LSZ 150 mcg Blotters (Lysergic Acid Derivative) – Scientific Product Description

Introduction

LSZ (Lysergic Acid 2,4-dimethylazetidide) is a semi-synthetic lysergamide, structurally related to LSD. These 150 mcg blotters were developed for use in strictly controlled laboratory environments and are intended for research into the pharmacological properties tai psychedelic compounds. Production takes place under strict quality control.

Tekniset tiedot

• Active ingredient: LSZ (Lysergic Acid 2,4-dimethylazetidide)
• Dosage per blotter: 150 ± 5 mcg
• Blotter size: 5×5 mm, perforated squares
• Carrier medium: High-quality chromatography paper
• Puhtaus: ≥98% (HPLC-analyysi)
• Shelf life: 24 months when stored between 2–8°C in a light-proof container.

Tutkimussovellukset

LSZ blotters are used in:

• Receptor binding studies targeting 5-HT2A agonism
• Comparative pharmacological analysis within the lysergamide class
• Dose-response studies in controlled models
• Metabolic stability studies in vitro

Quality control

Each batch is subjected to:

• HPLC-UV quantification of active substance
• Confirmation via mass spectrometry
• Dosage uniformity analysis
• Microbiological control of the carrier material

Turvallisuusprotokolla

Käsittely

• Use nitrile gloves for all handling
• Avoid direct contact with skin
• Work only in a controlled laboratory environment
• Wear protective clothing, goggles and, if necessary, respiratory protection

Storage

• Temperature: 2–8°C
• Protection from light and moisture is required
• Use only the original, sealed packaging

Regulatory Framework

• Classified under the Dutch Opium Act (Schedule I)
• Only permitted for licensed research institutions
• Not suitable for human consumption
• Export and distribution subject to regulations

Tilaustiedot

• Packaging unit: 10 blotters per sheet
• Delivery: Refrigerated transport with temperature registration
• Documentation: COA and full analytical specifications available per batch

Scientific References

• Nichols (2016) – Psykedeelit lääkkeinä
• Brandt ym. (2020) – Lysergamidin farmakologia
• EMCDDA (2023) – Tekninen raportti uusista psykoaktiivisista aineista

Important Note

This product is intended solely for legally authorized scientific research. Sale and use are restricted to qualified professionals within a regulated research environment. The purchaser is solely responsible for compliance with applicable laws and regulations.

1cP-LSD 150 MCG taidepaperia O-DSMT 50 mg -pelletit 1V-LSD 150 MCG -näytteenotot 6-CL-ADBA 2-CMC 250 mg -pellettiä